Product Images Fosamax Plus D

This text appears to be a graph showing the cumulative incidence over time (in months) for a placebo and FOSAMAX. No further information can be provided without a better context or a clear image of the graph.*

Description: The text is describing a study on the treatment of osteoporosis in postmenopausal women using Fosamax. The study measured the increase in bone mineral density (BMD) in the lumbar spine, femoral neck, and trochanter over the course of three years. The results show a significant increase in BMD compared to the placebo group.*

This is a table showing the mean percentage change from baseline of lumbar spine bone mineral density (BMD) in postmenopausal women with osteoporosis who were treated with FOSAMAX 10 mg/day versus placebo over time. The table also indicates the results of the US multinational study, with FOSAMAX showing a percent change of 10 at 10 months compared to placebo showing a percent change of 4 at 10 months. The SE (standard error) is also provided for each group at different time points.*

This is a medication label for Fosamax. The label specifies that this medication is dispensed in tablet form and contains 91.37 mg of alendronate sodium (70 mg free acid equivalent) and 70 mcg cholecalciferol, which is equivalent to 2800 1U vitamin D. The medication is intended for adults and should be taken once a week. Additional information, including the manufacturer and dosage information, can be found in the accompanying circular. The label also includes a space reserved for a 2D serialization barcode, serial number, expiry, and lot number.*

This text is a mix of errors, missing letters, and incomplete sentences. There is mention of FOSAMAX medication guide, dosage information, and prescription label. There is also a mention of a medication containing alendronate sodium and cholecalciferol. However, due to the issues and lack of full sentences, it is difficult to provide a useful description.*